An OpenData portal to share COVID-19 drug repurposing data in real time

  1. Kyle R. Brimacombe
  2. Tongan Zhao
  3. Richard T. Eastman
  4. Xin Hu
  5. Ke Wang
  6. Mark Backus
  7. Bolormaa Baljinnyam
  8. Catherine Z. Chen
  9. Lu Chen
  10. Tara Eicher
  11. Marc Ferrer
  12. Ying Fu
  13. Kirill Gorshkov
  14. Hui Guo
  15. Quinlin M. Hanson
  16. Zina Itkin
  17. Stephen C. Kales
  18. Carleen Klumpp-Thomas
  19. Emily M. Lee
  20. Sam Michael
  21. Tim Mierzwa
  22. Andrew Patt
  23. Manisha Pradhan
  24. Alex Renn
  25. Paul Shinn
  26. Jonathan H. Shrimp
  27. Amit Viraktamath
  28. Kelli M. Wilson
  29. Miao Xu
  30. Alexey V. Zakharov
  31. Wei Zhu
  32. Wei Zheng
  33. Anton Simeonov
  34. Ewy A. Mathé
  35. Donald C. Lo
  36. Matthew D. Hall
  37. Min Shen
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign – named OpenData – with the goal of making data across a range of SARS-CoV-2 related assays available in real-time. The assays developed cover a wide spectrum of the SARS-CoV-2 life cycle, including both viral and human (host) targets. In total, over 10,000 compounds are being tested in full concentration-response ranges from across multiple annotated small molecule libraries, including approved drug, repurposing candidates and experimental therapeutics designed to modulate a wide range of cellular targets. The goal is to support research scientists, clinical investigators and public health officials through open data sharing and analysis tools to expedite the development of SARS-CoV-2 interventions, and to prioritize promising compounds and repurposed drugs for further development in treating COVID-19.

Related articles

Related articles are currently not available for this article.